Search results
Showing 76 to 90 of 676 results for diabetes
Awaiting development Reference number: GID-TA10438 Expected publication date: TBC
Topic prioritisation
Type 2 diabetes: insulin degludec/liraglutide (Xultophy) (ESNM60)
Summary of the evidence on insulin degludec/liraglutide (Xultophy) for treating type 2 diabetes to inform local NHS planning and decision-making
This guideline covers preventing and managing foot problems in children, young people and adults with diabetes. It aims to reduce variation in practice, including antibiotic prescribing for diabetic foot infections.
This guideline covers managing acute and chronic pancreatitis in children, young people and adults. It aims to improve quality of life by ensuring that people have the right treatment and follow-up, and get timely information and support after diagnosis.
This indicator covers admission rates due to heart failure in people with diabetes. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as CCG61
This indicator covers the proportion of children and young people aged 12 to 18 years with type 2 diabetes who have a record of eye screening in the previous 24 months. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes
This indicator covers the proportion of children and young people aged 12 to 18 years with type 1 diabetes who have a record of eye screening in the previous 24 months. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes
Diabetes: lipid-lowering therapies for primary prevention of CVD (40 years and over) (IND275)
This indicator covers the percentage of patients with diabetes aged 40 years and over, with no history of cardiovascular disease and without moderate or severe frailty, who are currently treated with a lipid-lowering therapy (excluding patients with type 2 diabetes and a cardiovascular disease risk score of less than 10% recorded in the preceding 3 years). It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes
Diabetes: lipid-lowering therapies for primary prevention of CVD (T2DM and 10% risk) (IND274)
This indicator covers the percentage of patients with a diagnosis of type 2 diabetes and a recorded cardiovascular disease risk assessment score of 10% or more (without moderate or severe frailty), who are currently treated with a lipid-lowering therapy. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes
Diabetes mellitus type 1 and type 2: insulin glargine biosimilar (Abasaglar) (ESNM64)
Summary of the evidence on insulin glargine biosimilar (Abasaglar) for type 1 and type 2 diabetes mellitus to inform local NHS planning and decision-making
In development Reference number: GID-NG10336 Expected publication date: 18 February 2026
This indicator covers the percentage of patients with diabetes with a record of testing of foot sensation using a 10 g monofilament within the preceding 12 months. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as NM131
This indicator covers the percentage of patients with type 1 diabetes aged over 40 years (excluding people with a history of haemorrhagic stroke) who are currently treated with a lipid-lowering therapy. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes
This indicator covers the proportion of children and young people aged 12 to 18 years with type 2 diabetes who received individual care processes in the previous 12 months. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes